Activation of the RAS/RAF/MEK/ERK signalling pathway is found in the vast majority of melanomas and often occurs through mutations of either NRAS or BRAF (15–20% and 40–50% cutaneous melanomas, respectively)2, 3. Here, MAPK1 is linked to melanoma.